Peter Michael Ellis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter Michael Ellis has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Frances A. Shepherd
Medical Oncology Department, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
3 shared publications- Ming-Sound Tsao
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
3 shared publications - Geoffrey Liu
Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada
2 shared publications Lesley Seymour
NCIC Clinical Trials Group, Queen's University, ON, Canada
2 shared publicationsNormand Blais
Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
2 shared publicationsScott A. Laurie
Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada
2 shared publications
Latest Publications
- 1 November 2014
- Published by Elsevier in The Lancet Oncology
- Vol. 15 (12) , 1379-1388
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
- 1 November 2014
- Published by Elsevier in The Lancet Oncology
- Vol. 15 (12) , 1379-1388
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
Minimally invasive thoracic surgery for early stage non-small cell lung cancer
A safe alternative to open surgery for experienced surgeons in high volume hospitals Surgery for early stage non-small cell lung cancer remains the cornerstone of treatment. It allows complete resection of the tumor, accurate staging of the mediastinum, and more appropriate decision making about postoperative adjuvant chemotherapy. Open thoracotomy for lung cancer resections, however, carries associated risks of morbidity and mortality. Technological advances, such as video assisted thoracoscopic surgical techniques, offer the promise of reduced morbidity and improved surgical outcomes in comparison with open procedures.1 Data from randomized clinical trials evaluating this are lacking, however. One small randomized trial evaluated open versus thoracoscopic mediastinal lymph node dissection in stage I non-small cell lung cancer.2 No differences were observed in the number of lymph nodes retrieved. However, bias inherent in the design of existing published observational reports leaves uncertainty about the comparative effectiveness and safety of thoracoscopic versus open lobectomy. The linked paper by Paul and colleagues (doi:10.1136/bmj.g5575) goes some way towards reducing this uncertainty.3 The authors used data on Medicare recipients included in the US Surveillance Epidemiology and End Results (SEER) database to …
Minimally invasive thoracic surgery for early stage non-small cell lung cancer
A safe alternative to open surgery for experienced surgeons in high volume hospitals Surgery for early stage non-small cell lung cancer remains the cornerstone of treatment. It allows complete resection of the tumor, accurate staging of the mediastinum, and more appropriate decision making about postoperative adjuvant chemotherapy. Open thoracotomy for lung cancer resections, however, carries associated risks of morbidity and mortality. Technological advances, such as video assisted thoracoscopic surgical techniques, offer the promise of reduced morbidity and improved surgical outcomes in comparison with open procedures.1 Data from randomized clinical trials evaluating this are lacking, however. One small randomized trial evaluated open versus thoracoscopic mediastinal lymph node dissection in stage I non-small cell lung cancer.2 No differences were observed in the number of lymph nodes retrieved. However, bias inherent in the design of existing published observational reports leaves uncertainty about the comparative effectiveness and safety of thoracoscopic versus open lobectomy. The linked paper by Paul and colleagues (doi:10.1136/bmj.g5575) goes some way towards reducing this uncertainty.3 The authors used data on Medicare recipients included in the US Surveillance Epidemiology and End Results (SEER) database to …
- 1 July 2014
- Published by Elsevier in Clinical Lung Cancer
- Vol. 15 (4) , 274-280
Stage III Non–Small-Cell Lung Cancer: Establishing a Benchmark for the Proportion of Patients Suitable for Radical Treatment
- 1 July 2014
- Published by Elsevier in Clinical Lung Cancer
- Vol. 15 (4) , 274-280
Stage III Non–Small-Cell Lung Cancer: Establishing a Benchmark for the Proportion of Patients Suitable for Radical Treatment
- Open Access
- 27 June 2014
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 4, 157
Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
Historically, the treatment algorithm applied to non small cell lung cancer (NSCLC) was the same for all histologic subtypes. However, recent advances in our understanding of the molecular profiles of squamous and non-squamous NSCLC have changed this perspective. Histologic subtype and the presence of specific molecular abnormalities have predictive value for response to and toxicity from therapy, as well as overall survival. For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy. The role of EGFR monoclonal antibodies is uncertain. Maintenance therapy is not widely recommended, although data exist for the use of erlotinib. The standard recommendation for second-line therapy is docetaxel and erlotinib should be considered as second or third-line therapy. There is ongoing research identifying molecular targets in squamous NSCLC and many agents are in early phase clinical trials. Immunotherapeutic approaches targeting programmed death 1 receptor (PD-1) and its ligand (PD-L1) appear promising.
- 27 June 2014
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 4, 157
Open AccessTreatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
Historically, the treatment algorithm applied to non small cell lung cancer (NSCLC) was the same for all histologic subtypes. However, recent advances in our understanding of the molecular profiles of squamous and non-squamous NSCLC have changed this perspective. Histologic subtype and the presence of specific molecular abnormalities have predictive value for response to and toxicity from therapy, as well as overall survival. For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy. The role of EGFR monoclonal antibodies is uncertain. Maintenance therapy is not widely recommended, although data exist for the use of erlotinib. The standard recommendation for second-line therapy is docetaxel and erlotinib should be considered as second or third-line therapy. There is ongoing research identifying molecular targets in squamous NSCLC and many agents are in early phase clinical trials. Immunotherapeutic approaches targeting programmed death 1 receptor (PD-1) and its ligand (PD-L1) appear promising.
- Open Access
- 22 March 2014
- Published by Springer Nature in Implementation Science
- Vol. 9 (1) , 36
A mixed methods approach to understand variation in lung cancer practice and the role of guidelines
Practice pattern data demonstrate regional variation and lower than expected rates of adherence to practice guideline (PG) recommendations for the treatment of stage II/IIIA resected and stage IIIA/IIIB unresected non-small cell lung cancer (NSCLC) patients in Ontario, Canada. This study sought to understand how clinical decisions are made for the treatment of these patients and the role of PGs.
- 22 March 2014
- Published by Springer Nature in Implementation Science
- Vol. 9 (1) , 36
Open AccessA mixed methods approach to understand variation in lung cancer practice and the role of guidelines
Practice pattern data demonstrate regional variation and lower than expected rates of adherence to practice guideline (PG) recommendations for the treatment of stage II/IIIA resected and stage IIIA/IIIB unresected non-small cell lung cancer (NSCLC) patients in Ontario, Canada. This study sought to understand how clinical decisions are made for the treatment of these patients and the role of PGs.
- 1 March 2014
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 9 (3) , 410-413
NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer
- 1 March 2014
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 9 (3) , 410-413
NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer
- 1 September 2013
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 8 (9) , 1136-1141
Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non–Small-Cell Lung Cancer in a Publicly Funded Health Care System
- 1 September 2013
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 8 (9) , 1136-1141
Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non–Small-Cell Lung Cancer in a Publicly Funded Health Care System
- Open Access
- 1 August 2013
- Published by MDPI AG in Current Oncology
- Vol. 20 (4) , 300-306
Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases
Background: The prognosis of patients with brain metastases from non-small-cell lung cancer (NSCLC) is poor. However, some reports suggest that patients with brain metastases at the time of initial diagnosis have a more favourable survival than do patients with advanced NSCLC without brain metastases. Methods: In a retrospective cohort of all new lung cancer patients seen at a Canadian tertiary centre between July 2005 and June 2007, we examined survival after a diagnosis of brain metastases for patients with brain metastases at initial diagnosis and patients who developed brain metastases later in their illness. Results: During the 2-year period, 91 of 878 patients (10.4%) developed brain metastases. Median age in this cohort was 64 years. In 45, brain metastases were present at initial diagnosis, and in 46, brain metastases developed later in the course of the illness. Median survival in the entire cohort was 7.8 months. Survival after the diagnosis of brain metastases was similar for patients with brain metastases at diagnosis and later in the illness (4.8 months vs. 3.7 months, p = 0.53). As a result, patients who developed brain metastases later in their illness had a longer overall survival than did patients with brain metastases at diagnosis (9.8 months vs. 4.8 months). Among patients who received chemotherapy, the survival of patients with brain metastases at diagnosis was still poor (6.2 months). Conclusions: Our data show limited survival in patients with brain metastases from NSCLC. Careful patient selection for more aggressive treatment approaches is necessary.
- 1 August 2013
- Published by MDPI AG in Current Oncology
- Vol. 20 (4) , 300-306
Open AccessSurvival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases
Background: The prognosis of patients with brain metastases from non-small-cell lung cancer (NSCLC) is poor. However, some reports suggest that patients with brain metastases at the time of initial diagnosis have a more favourable survival than do patients with advanced NSCLC without brain metastases. Methods: In a retrospective cohort of all new lung cancer patients seen at a Canadian tertiary centre between July 2005 and June 2007, we examined survival after a diagnosis of brain metastases for patients with brain metastases at initial diagnosis and patients who developed brain metastases later in their illness. Results: During the 2-year period, 91 of 878 patients (10.4%) developed brain metastases. Median age in this cohort was 64 years. In 45, brain metastases were present at initial diagnosis, and in 46, brain metastases developed later in the course of the illness. Median survival in the entire cohort was 7.8 months. Survival after the diagnosis of brain metastases was similar for patients with brain metastases at diagnosis and later in the illness (4.8 months vs. 3.7 months, p = 0.53). As a result, patients who developed brain metastases later in their illness had a longer overall survival than did patients with brain metastases at diagnosis (9.8 months vs. 4.8 months). Among patients who received chemotherapy, the survival of patients with brain metastases at diagnosis was still poor (6.2 months). Conclusions: Our data show limited survival in patients with brain metastases from NSCLC. Careful patient selection for more aggressive treatment approaches is necessary.
- 1 April 2013
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 8 (4) , 423-428
A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer
- 1 April 2013
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 8 (4) , 423-428
A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer
- 1 January 2013
- Published by Elsevier in Clinical Lung Cancer
- Vol. 14 (1) , 19-27
A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer
- 1 January 2013
- Published by Elsevier in Clinical Lung Cancer
- Vol. 14 (1) , 19-27
A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer